lisocabtagene maraleucel 对比 axicabtagene ciloleucel 用于早期复发/难治性大 B 细胞淋巴瘤患者二线治疗的匹配调整间接比较

In the absence of head-to-head trials of chimeric antigen receptor T-cell therapies, a matching-adjusted indirect comparison (MAIC) evaluated the comparative efficacy and safety of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) as second-line (2L) therapies in patients with early relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Data sources were the pivotal phase 3 trials: individual patient-level data from TRANSFORM [liso-cel (NCT03575351), N = 184] and summary-level data from ZUMA-7 [axi-cel (NCT03391466), N = 359].

Efficacy analyses were anchored via the common standard-of-care comparator arms and showed no statistically significant differences. Safety analyses were unanchored, showing liso-cel had lower odds (95% confidence interval) of grade 3 serious treatment-emergent adverse events [0. 49 (0. 27-0.

90)], cytokine release syndrome [any grade, 0. 09 (0. 04-0. 18); grade 3, 0. 09 (0. 01-0. 75)], and neurological events [any grade, 0. 08 (0. 03-0. 18); grade 3, 0. 21 (0. 06-0. 68)]. In this MAIC, liso-cel demonstrated comparable efficacy and a more favorable safety profile versus axi-cel for 2L treatment of R/R LBCL.